Instalab

Cat (Fel d 1) IgE Test Blood

Pinpoint whether cats are actually triggering your sniffles, wheezing, or asthma, with more precision than a general cat allergy test.

Should you take a Cat (Fel d 1) IgE test?

This test is most useful if any of these apply to you.

Sneezing or Wheezing Around Cats
Confirm whether cats are actually triggering your symptoms or whether something else in the environment is to blame.
Managing Asthma
High cat-specific antibody levels are linked to asthma severity, even if you don't currently live with a cat.
Parent of an Allergic Child
Childhood sensitization to cat protein predicts later cat allergy and asthma, often years before symptoms appear.
Considering Allergy Immunotherapy
Pinpointing the exact cat protein driving your reaction helps your allergist choose the most targeted treatment plan.

About Cat (Fel d 1) IgE

If you sneeze around cats, wake up congested at a friend's apartment, or notice your asthma flaring after petting one, this test answers a specific question: is the cat actually the problem, and how strong is your immune reaction to it? The protein called Fel d 1 (short for Felis domesticus allergen 1) is the dominant trigger of cat allergy, accounting for 50 to 90 percent of the allergenic activity in cat dander.

Roughly 85 to 100 percent of cat-allergic people carry IgE antibodies (the immune molecules behind allergic reactions) against Fel d 1, often at the highest levels of any cat-related antibody. Knowing your number does more than confirm a hunch. It can sort genuine cat allergy from look-alike cross-reactions, predict how severe your symptoms might become, and guide whether targeted treatments like immunotherapy are worth pursuing.

What This Test Actually Measures

This test measures IgE (immunoglobulin E, the antibody class your body produces in allergic responses) that specifically binds to Fel d 1. Fel d 1 belongs to a family of small secreted proteins called secretoglobins, and cats produce it in their skin, saliva, hair, and urine. When you breathe in microscopic flakes of cat dander, your immune system can recognize Fel d 1 as a threat and produce IgE antibodies against it.

Those antibodies then sit on the surface of mast cells and basophils (the immune cells that release histamine and other inflammatory chemicals). The next time you encounter cat allergen, the IgE triggers those cells to fire, producing the runny nose, itchy eyes, hives, or wheezing you experience. The blood test quantifies how much of this Fel d 1-specific IgE is circulating in your serum.

Why a Component Test Beats a Generic Cat Allergy Panel

A standard cat allergy test uses whole cat dander extract, which contains many proteins. Some of those proteins cross-react with allergens from other animals, leading to false positives in people who are actually allergic to dogs or even cattle. The Fel d 1 test isolates the single most important cat protein, giving you a cleaner read on whether cats specifically are driving your symptoms.

In dog-exclusive owners who tested positive for cat dander extract, measuring Fel d 1 IgE separated true cat sensitization from cross-reactive antibodies tied to their dogs. In a separate analysis of allergy patients with rhinitis, skin prick testing caught more total cat reactions, but Fel d 1 IgE testing was more specific, meaning fewer false alarms. The two approaches are complementary: extract testing is more sensitive, while Fel d 1 testing is more precise about what your immune system is actually targeting.

Asthma Risk and Severity

Higher Fel d 1 IgE titers track closely with asthma diagnosis, severity, and persistence. In a study of 963 nineteen-year-olds in northern Sweden, high-titer cat-specific IgE was strongly associated with asthma even in people who did not currently live with a cat. In a cohort of 779 children followed into adolescence, childhood sensitization to Fel d 1 predicted cat-allergy symptoms at age 16 better than testing with whole cat extract.

The pattern matters too. People sensitized to multiple cat components (Fel d 1 plus others like Fel d 4 or Fel d 7) tend to have more complex disease, often including skin involvement on top of respiratory symptoms. In one study of 500 allergic patients, polysensitization was present in 81 percent and was linked to greater asthma and rhinitis severity. Childhood sensitization to grass and cat allergens together has been identified as one of the strongest early predictors of later asthma.

Allergic Rhinitis and Eye Symptoms

Cat-allergic rhinitis (the runny nose, sneezing, and nasal congestion triggered by cat exposure) is the most common manifestation of Fel d 1 sensitization. Among 84 cat-allergic adults and children studied for molecular IgE patterns, Fel d 1 was the dominant marker across phenotypes, including those with rhinoconjunctivitis. The higher and broader your IgE response across cat proteins, the more likely your symptoms extend beyond the nose into the eyes, chest, or skin.

Early Detection Years Before Symptoms

Fel d 1 sensitization can show up in blood years before any cat-related symptoms appear. In the BAMSE birth cohort, recombinant Fel d 1 IgE testing identified cat sensitization in children well before they developed clinical allergy. This early-warning capacity makes the test useful not just for confirming current allergy but for understanding immune trajectory in children at risk.

Tracking Your Trend

A single Fel d 1 IgE result is a snapshot, not a complete picture. The number can shift based on recent exposure, immune activity, and underlying sensitization changes. If you are pursuing allergen immunotherapy, biologic therapy, or major changes in your environment, serial testing tells you what your baseline really is and whether your immune response is stable, rising, or shifting.

That said, an important caveat applies. In clinical trials of subcutaneous cat immunotherapy, peptide immunotherapy, intralymphatic recombinant Fel d 1 immunotherapy, and anti-Fel d 1 monoclonal antibodies, Fel d 1-specific IgE levels often remained stable over months to a year despite symptom improvement. The clinical benefit came from blocking IgE-allergen interaction or shifting to protective IgG4 antibodies, not from IgE disappearing. Even moving out of a cat-owning home did not significantly drop established Fel d 1 IgE over 8 to 24 months in college students.

What this means practically: if your IgE level stays high while your symptoms improve on therapy, that does not mean treatment is failing. Track symptoms, IgG4 if available, and Fel d 1 IgE together for a fuller picture. A reasonable cadence is a baseline test, retest in 6 to 12 months if starting immunotherapy or making major environmental changes, then at least annually thereafter.

Reconciling the Stability Puzzle

It can be confusing that treatments which clearly help cat-allergic patients often leave their Fel d 1 IgE numbers nearly unchanged. The resolution is straightforward: Fel d 1 IgE measures whether your immune system has learned to recognize cat allergen, not whether that recognition is currently triggering inflammation. Therapy can muffle the downstream allergic response (by producing blocking antibodies or dampening Th2 cells, the immune cells that drive allergic inflammation) without erasing the underlying IgE memory. Think of the IgE as a record of past sensitization, while symptoms reflect how loudly that record is currently being played.

When Results Can Be Misleading

A few situations can distort your interpretation of a Fel d 1 IgE result:

  • Cross-reactivity confusion: if you use whole cat dander extract testing alone, dog allergens or other animal proteins can produce positive cat results even without true cat allergy. Fel d 1 component testing solves this, but make sure that is what was ordered.
  • Other cat components driving symptoms: absent or low Fel d 1 IgE does not rule out cat allergy entirely. You may have IgE to Fel d 2 (cat albumin), Fel d 4, or Fel d 7 instead. These secondary sensitizations can still cause symptoms and sometimes signal cross-reactivity to dog, pork, or beef.
  • Recent anti-Fel d 1 monoclonal antibody therapy: experimental treatments like REGN1908-1909 block Fel d 1 functionally without changing your measured IgE level for 8 to 12 weeks after dosing.
  • Assay differences: recombinant Fel d 1 assays can yield higher numerical readings than crude extract-based tests, so comparing results across different lab platforms can mislead. Stick with the same test method for trend tracking.

Decision Pathway for Out-of-Pattern Results

If your Fel d 1 IgE comes back elevated and your symptoms match (sneezing, congestion, wheezing, or hives around cats), the next step is deciding what to do about it. Consider adding a broader cat component panel (Fel d 2, Fel d 4, Fel d 7) if your symptoms include systemic features like severe asthma, skin involvement, or unexplained reactions to red meat. Pair this with general aeroallergen testing if you are pursuing allergy immunotherapy, since polysensitization changes the treatment approach.

If your Fel d 1 IgE is high but you have no symptoms, that often reflects sensitization without active allergy. Track it over time and stay alert for new symptoms, especially if you have a strong family history of asthma. If your Fel d 1 IgE is low or undetectable but you have clear cat-triggered symptoms, ask your allergist about extended cat component testing, skin prick testing, or evaluation for non-IgE mechanisms. An allergist or immunologist is the right specialist to interpret unexpected patterns, especially if you are considering immunotherapy or anti-IgE biologics.

What Moves This Biomarker

Evidence-backed interventions that affect your Cat (Fel d 1) IgE level

Increase
Subcutaneous cat allergen immunotherapy (standardized cat extract injections)
Standard allergy shots using cat dander extract typically reduce symptoms by shifting your immune response, but measured Fel d 1-specific IgE levels generally do not decrease meaningfully within the first year of treatment. In a randomized trial of 28 cat-allergic adults receiving 0.6, 3, or 15 micrograms of Fel d 1 per injection, the primary immunologic changes were a large increase in blocking IgG4 antibodies and a reduction in Th2 cells at the highest dose, not a fall in Fel d 1 IgE itself. The clinical benefit comes from these other shifts, not from IgE reduction.
MedicationModest Evidence
Increase
Intralymphatic immunotherapy with recombinant MAT-Fel d 1
Three injections of recombinant Fel d 1 directly into a lymph node produced a marked increase in protective IgG4 and IgG2 antibodies but left Fel d 1-specific IgE levels essentially unchanged over 12 months of follow-up. The benefit comes from antibody class shifting and immune tolerance, not from lowering measured IgE.
MedicationModest Evidence
Increase
Anti-Fel d 1 monoclonal antibodies (REGN1908-1909)
A single subcutaneous dose of human monoclonal antibodies that bind and neutralize Fel d 1 improved nasal symptoms in cat-allergic adults and suppressed type 2 cytokines (IL-4, IL-5, IL-13). Despite functional blocking of Fel d 1, both total IgE and Fel d 1-specific IgE remained unchanged for the 113-day follow-up period. This treatment changes how IgE behaves, not how much there is.
MedicationModest Evidence
Increase
Fel d 1 peptide immunotherapy
Six weekly injections of short Fel d 1-derived T-cell peptides (at 7.5, 75, or 750 micrograms) significantly reduced IL-4 release from blood T cells in cat-allergic adults at the highest dose. Bronchial hyperresponsiveness improved within higher-dose groups. However, Fel d 1-specific IgE and IgG levels did not change over the roughly 3-month observation period. The mechanism is T-cell modulation, not antibody reduction.
MedicationModest Evidence
Increase
Sustained reduction of cat exposure (moving out of cat-owning environment)
Moving from a cat-owning home to low-exposure housing did not significantly lower established Fel d 1-specific IgE over 8 months or even 2 years in college students who were already sensitized. Fel d 1-specific IgG and IgG4 did drop substantially in the same period. The lab number tends to persist even after the environmental trigger is removed, though removing exposure still reduces symptoms and prevents new sensitization in non-allergic people.
LifestyleModest Evidence

Frequently Asked Questions

References

22 studies
  1. Riabova K, Karsonova a, Van Hage M, Käck U, Konradsen J, Grönlund H, Fomina D, Beltyukov E, Glazkova P, Semenov D, Valenta R, Karaulov a, Curin MInternational Journal of Molecular Sciences2022
  2. Trifonova D, Curin M, Riabova K, Karsonova a, Keller W, Grönlund H, Käck U, Konradsen J, Van Hage M, Karaulov a, Valenta RInternational Journal of Molecular Sciences2023
  3. Eidukaitė a, Gorbikova E, Miškinytė M, Adomaite I, Rudzevičienė O, ŠIaurys a, Miskiniene aThe World Allergy Organization Journal2023
  4. Asarnoj a, Hamsten C, Wadén K, Lupinek C, Andersson N, Kull I, Curin M, Anto J, Bousquet J, Valenta R, Wickman M, Van Hage MThe Journal of Allergy and Clinical Immunology2016
  5. Curin M, Swoboda I, Wollmann E, Lupinek C, Spitzauer S, Van Hage M, Valenta RThe Journal of Allergy and Clinical Immunology2014